L
Li Shen
Researcher at University of Texas MD Anderson Cancer Center
Publications - 269
Citations - 7735
Li Shen is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 36, co-authored 222 publications receiving 5894 citations. Previous affiliations of Li Shen include Johns Hopkins University & Life Sciences Institute.
Papers
More filters
Journal ArticleDOI
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai T. Tran,Robert J. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy L. Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun Ki Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach +33 more
TL;DR: A robust EMT signature is developed that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance associated with the mesenchyal phenotype.
Journal ArticleDOI
Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites.
TL;DR: A wide range of methods exists to detect genomic DNA methylation, in-cluding approaches to detect genome-wide and gene-specific methylation lev-els, and recently, high-throughput methods to detect site-spe-cific methylation have been developed using the TaqMan.
Journal ArticleDOI
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James W. Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach +27 more
TL;DR: SCLC was significantly more sensitive to PARP inhibitors than were NSCLCs, and PARP inhibition downregulated key components of the DNA repair machinery and enhanced the efficacy of chemotherapy.
Journal ArticleDOI
Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma
Ashley Orillion,Ashley Orillion,Ayumi Hashimoto,Nur P. Damayanti,Li Shen,Remi Adelaiye-Ogala,Remi Adelaiye-Ogala,Sreevani Arisa,Sreenivasulu Chintala,Peter Ordentlich,Chinghai Kao,Bennett D. Elzey,Bennett D. Elzey,Dmitry I. Gabrilovich,Roberto Pili +14 more
TL;DR: The results demonstrate that entinostat enhances the antitumor effect of PD-1 targeting through functional inhibition of MDSCs and a transition away from an immune-suppressive tumor microenvironment.
Journal ArticleDOI
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Ana Aparicio,Li Shen,Elsa M. Li Ning Tapia,Jing-Fang Lu,Hsiang-Chun Chen,Jiexin Zhang,Guanglin Wu,Xuemei Wang,Patricia Troncoso,Paul G. Corn,Timothy C. Thompson,Bradley M. Broom,Keith A. Baggerly,Sankar N. Maity,Christopher J. Logothetis +14 more
TL;DR: Clinically defined AVPC share molecular features with SCPC and are characterized by combined alterations in RB1, Tp53, and/or PTEN, which was the strongest discriminator between unselected castration-resistant prostate cancer (CRPC) and the AVPC.